USA flag logo/image

An Official Website of the United States Government

LIVE ATTENUATED BACTERIAL VACCINES AGAINST ANTHRAX

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60594
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
AI053021
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AVANT IMMUNOTHERAPEUTICS, INC.
AVANT IMMUNOTHERAPEUTICS, INC. 119 4TH AVE NEEDHAM, MA 02494 0272
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: LIVE ATTENUATED BACTERIAL VACCINES AGAINST ANTHRAX
Agency: HHS
Contract: 1R43AI053021-01
Award Amount: $120,511.00
 

Abstract:

DESCRIPTION (provided by applicant): The ability to prepare anthrax spores inexpensively and deliver them in an aerosol form, and the high mortality rate of inhalation anthrax, has made Bacillus anthracis one of the most feared agents of biological warfare and terrorism. Despite recent advances in understanding anthrax, no sustained effort has been made to develop new prophylactic or therapeutic agents to protect or treat against the disease. The current anthrax vaccine (AVA) consists of an alum-adsorbed culture filtrate, principally containing the anthrax toxin protective antigen (PA), from an attenuated strain of B. anthracis. Immunization with AVA requires multiple doses over 18 months and occasionally produces local reactogenicity in vaccinees. Accordingly, there is a critical requirement for an improved anthrax vaccine. The delivery of foreign antigens using live vectors is well suited for vaccines against diseases in which a rapid immune response against an antigen(s) is important for protection. The goal of this proposal is to evaluate the potential of live, attenuated strains of Vibrio cholerae and Salmonella typhimurium expressing PA, as improved anthrax vaccines. The Specific Aims of this project are to (1) construct attenuated V. cholerae and S. typhimurium vectors expressing recombinant PA, (2) evaluate the colonization and immunogenicity of (1) in pre-clinical models, and (3) evaluate the efficacy of (1) using anthrax toxin challenge in appropriate animal models. The successful accomplishment of these aims will provide new anthrax vaccines with the potential to confer protective immunity by oral immunization in humans.

Principal Investigator:

Sims K. Kochi
7814333161
SKOCHI@AVANTIMMUNE.COM

Business Contact:

Una Ryan
7814330771
URYAN@AVANTIMMUNE.COM
Small Business Information at Submission:

AVANT IMMUNOTHERAPEUTICS, INC.
AVANT IMMUNOTHERAPEUTICS, INC. 119 4TH AVE NEEDHAM, MA 02494

EIN/Tax ID: 133191702
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No